Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest PharmaTechQPTFF EV-to-EBITDA is 1.03 as of Aug. 13, 2026. Among 399 Biotechnology companies, Quest PharmaTech ranks better than 80.2% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Quest PharmaTech's enterprise value is $3.74 Mil.
Quest PharmaTech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 was $3.62 Mil. Therefore, Quest PharmaTech's EV-to-EBITDA for today is 1.03.
The historical rank and industry rank for Quest PharmaTech's EV-to-EBITDA or its related term are showing as below:
QPTFF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.91 Med: -8.68 Max: 0.87
Current: 0.87
During the past 13 years, the highest EV-to-EBITDA of Quest PharmaTech was 0.87. The lowest was -22.91. And the median was -8.68.
QPTFF's EV-to-EBITDA is ranked better than 80.2% of 399
companies
in the Biotechnology industry
Industry Median: 13.39
vs QPTFF: 0.87
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Quest PharmaTech's PE Ratio (TTM) for today is calculated as:
Quest PharmaTech's share price for today is $0.02.
Quest PharmaTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Quest PharmaTech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QPTFF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Quest PharmaTech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest PharmaTech EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quest PharmaTech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Quest PharmaTech's EV-to-EBITDA falls into.
Quest PharmaTech's current Enterprise Value is $3.74 Mil.
Quest PharmaTech's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest PharmaTech (QPTFF) has a EV-to-EBITDA of 1.03 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Quest PharmaTech. According to the industry distribution chart, Quest PharmaTech ranks #79 out of 399 companies in the Biotechnology industry, placing it in the top 19.8%.
Is Quest PharmaTech's EV-to-EBITDA too high?
Quest PharmaTech's current EV-to-EBITDA is 1.03. The Biotechnology industry median EV-to-EBITDA is 13.39. Quest PharmaTech's value of 1.03 is 92.3% below this industry median. Based on the distribution chart, Quest PharmaTech ranks #79 out of 399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Quest PharmaTech's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quest PharmaTech ranks #79 out of 399 companies for EV-to-EBITDA. This places Quest PharmaTech in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.39. Quest PharmaTech's value of 1.03 is 92.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.39, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest PharmaTech's current EV-to-EBITDA of 1.03 is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Quest PharmaTech. For the Biotechnology industry, the median EV-to-EBITDA is 13.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest PharmaTech's current EV-to-EBITDA is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current EV-to-EBITDA of 1.03. The current EV-to-EBITDA is 1.03 and 92.3% below the Biotechnology industry median of 13.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current EV-to-EBITDA is 1.03 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QPTFF has been successfully added to your 
